Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18488334 | 0.84 | GPR84 (0.42) | GPR84IGF1RSTK17ACNR1STK17B | |
| SCHEMBL18488672 | 0.82 | MEN1 (0.50) | GPR84STK17ASTK17BKMT2ATAAR1 | |
| SCHEMBL30395436 | 0.76 | CCND3 (0.53) | GPR84STK17ASTK17BTAAR1ALDH1A1 | |
| SCHEMBL20421838 | 0.76 | CCND3 (0.53) | GPR84STK17ASTK17BTAAR1ALDH1A1 | |
| SCHEMBL18493897 | 0.76 | STK17B (0.43) | STK17ASTK17BKMT2ATAAR1 | |
| SCHEMBL18488360 | 0.75 | APP (0.60) | STK17ASTK17BKMT2A | |
| SCHEMBL29555879 | 0.75 | APP (0.60) | STK17ASTK17BKMT2A | |
| SCHEMBL18488448 | 0.75 | HDAC3 (0.47) | STK17ASTK17BTAAR1ALDH1A1 | |
| SCHEMBL21214764 | 0.73 | HPGD (0.45) | STK17AKMT2AALDH1A1HPGDP2RX7 | |
| SCHEMBL18488988 | 0.73 | JAK2 (0.56) | STK17ACNR1STK17BKMT2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2017023899-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | GPR84 2639/4885IGF1R 857/4885STK17A 23/4885 |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | GPR84 2639/4885IGF1R 857/4885STK17A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.